Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Understanding the Role of Mineralocorticoid Receptor Antagonists and the Impact on Patient Care in Chronic Kidney Disease in Type 2 Diabetes

Credits Available
Pharmacists: 1.5 contact hours (0.15 CEUs)
Released: April 29, 2022 Expiration: April 28, 2023
Start Activity
Provided by ProCE, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.
Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP
Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the pathophysiology and renal and cardiovascular outcomes of mineralocorticoid receptor activation in chronic kidney disease in patients with type 2 diabetes
  • Evaluate the safety and efficacy evidence of the selective nonsteroidal mineralocorticoid receptor antagonist finerenone
  • Compare the clinical differences between steroidal and selective nonsteroidal mineralocorticoid receptor antagonists
  • Identify appropriate candidates for finerenone and strategies to implement use, including multidisciplinary care and overcoming clinical inertia

Information on this Educational Activity

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP

Endocrine Clinical Pharmacy Specialist
CGM and Remote Monitoring Program Coordinator

Endocrinology and Metabolism Institute
Cleveland Clinic
Cleveland, Ohio

Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP, has disclosed that she has received consulting fees from Abbott, Dexcom, Insulet, Klinio, Medtronic, and Novo Nordisk.
Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP

Vice Chair & Allen I. White Distinguished Professor
Department of Pharmacotherapy
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, Washington

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, has disclosed that he has received consulting fees from Bayer, Dexcom, Novo Nordisk, and Sanofi.

Staff

Robin Black, PharmD, BCACP

Scientific Director

Robin Black, PharmD, BCACP has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The target audience for this activity is pharmacists, including community, ambulatory care, primary care, and clinical pharmacists, who care for patients with CKD and T2D as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Goal

The goal of this activity is to improve the knowledge and competence of pharmacists about pathophysiology of mineralocorticoid receptor activation in CKD in patients with T2D and the impact of the selective nonsteroidal mineralocorticoid receptor antagonist finerenone on patient care.

Continuing Pharmacy Education

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-093-H01-P has been assigned to this home study, application-based activity. This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 29, 2022, through April 28, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Understanding the Role of Mineralocorticoid Receptor Antagonists and the Impact on Patient Care in Chronic Kidney Disease in Type 2 Diabetes

Loading...
In this interactive, on-demand webcast, experts provide insights on the evidence behind the use of finerenone in diabetic kidney disease, selecting appropriate patients for finerenone therapy, and strategies for overcoming clinical inertia.
Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP
Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP
Pharmacists: 1.5 contact hours (0.15 CEUs)
Released: April 29, 2022 Expiration: April 28, 2023

Related Content

Expert faculty provide practical strategies for successful implementation of digital techonologies to improve diabetes outcomes from ProCE

Andrew Bzowyckyi, PharmD, BCPS, CDCES Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP Pharmacists: 1.5 contact hours (0.15 CEUs) Released: April 18, 2022 Expired: April 17, 2023

Expert commentary on the pharmacist’s role in helping persons with obesity navigate weight loss from Clinical Care Options (CCO)

Megan Adelman, PharmD, BCPS, BCGP, CDCES Elizabeth Pogge, PharmD, MPH, BCPS-AQ Cardiology, BCGP, FASCP, FAzPA Released: April 8, 2022

Slideset with expert insights addressing practical strategies for successful implementation of digital techonologies to improve diabetes outcomes from ProCE

Andrew Bzowyckyi, PharmD, BCPS, CDCES Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP Released: March 18, 2022

Slide set with expert insight on evidence for finerenone use in DKD, selecting patients for therapy, and overcoming clinical inertia from ProCE

Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP Released: March 18, 2022
Provided by ProCE, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings